|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.47/-0.61
|
企业价值
558.85M
|
资产负债 |
每股账面净值
2.88
|
现金流量 |
现金流量率
--
|
损益表 |
收益
67.42M
|
每股收益
0.18
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/29 08:56 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac's first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipelinecandidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases. |